Cancer Surveillance and Age: When Risk, Benefit and Priorities Shift
This article forms part of Dr Deanne Soares’ urologic cancer education series, providing evidence-based guidance on treatment, recovery and life after urological cancer surgery.
Age is one of the most influential — and most misunderstood — factors in cancer decision-making.
For many patients, growing older raises difficult questions:
Is treatment still worthwhile?
Is surveillance safer — or riskier?
At what point does “doing less” become the right choice?
In urologic cancer care, age alone should never determine treatment. What matters is how age intersects with cancer biology, overall health, functional reserve and personal priorities. This article explores how surveillance and treatment decisions evolve over time, and why those decisions often look different later in life.
Patient summary
Age alone does not determine cancer treatment
Health, function and priorities matter more than a number
Surveillance may become more appropriate over time
Treatment decisions can change as circumstances change
Good care adapts as life evolves
Why age changes the conversation
As people age, several things tend to shift simultaneously:
the pace of life slows
health priorities broaden
tolerance for treatment side effects changes
competing medical conditions become more relevant
At the same time, many urologic cancers — particularly prostate and some kidney cancers — often behave slowly.
The result is a more nuanced balance between:
cancer control
treatment burden
quality of life
remaining life expectancy
This balance is not static. It evolves.
Age is not the same as frailty
One of the most important distinctions in cancer care is between chronological age and physiological age.
Two people of the same age can have vastly different:
cardiovascular fitness
kidney function
cognitive reserve
independence and resilience
A fit, active 75-year-old may tolerate and benefit from treatment far more than a younger person with significant comorbidities.
Good decision-making looks beyond the birth date.
Where surveillance becomes more attractive with age
Active surveillance may become increasingly appropriate when:
cancer is low-risk or slow-growing
competing health issues are more likely to influence lifespan
treatment side effects would significantly affect independence
the individual values stability over intervention
In these situations, surveillance can protect quality of life without meaningfully increasing cancer-related risk.
Importantly, this is not about “giving up”. It is about proportional care.
When treatment still makes sense later in life
Age does not automatically rule out surgery or other treatments.
Treatment may still be recommended when:
cancer biology suggests meaningful risk
life expectancy is sufficient to benefit
functional reserve is strong
the individual prioritises active intervention
Some older patients value cancer control above all else. Others value maintaining independence or avoiding prolonged recovery. Neither perspective is wrong.
How priorities shift over time
Patients often notice that their priorities change as they age.
Earlier in life, the focus may be on:
long-term cancer control
minimising recurrence risk
aggressive treatment
Later, priorities may shift toward:
maintaining independence
avoiding hospitalisation
preserving continence, energy and cognition
staying engaged in daily life
Revisiting decisions as priorities change is not inconsistency. It is responsiveness.
Surveillance is not a “one-way door”
A common fear is that choosing surveillance means losing the opportunity for treatment.
In reality:
surveillance is monitored
triggers for treatment are predefined
decisions are revisited regularly
For some patients, surveillance remains appropriate indefinitely. For others, treatment becomes the better choice as circumstances evolve. Both paths are valid.
The role of the GP in ageing and surveillance
GPs play a central role in this phase of care by:
contextualising cancer risk within overall health
managing comorbidities that influence decision-making
supporting discussions about goals and values
recognising when reassessment is needed
For many older patients, trusted GP input is critical to feeling confident in a surveillance-based approach.
Family involvement and decision-making
As patients age, family members often become more involved in care decisions.
This can be helpful — but also challenging — particularly when perspectives differ.
Clear, shared discussions that focus on:
what the cancer is likely to do
what treatment would involve
what the patient values most
help reduce conflict and guilt, and support aligned decision-making.
Surgical judgement and proportional care
In practice, caring for older patients with urologic cancer requires comfort with both intervention and restraint.
Experience across the full spectrum of disease allows recommendations to be tailored — not only to the cancer, but to the person living with it.
Proportional care is not about doing less because someone is older. It is about doing what adds value — and avoiding what does not.
A note on individual decision-making
This information is intended to provide general guidance on how age influences cancer surveillance and treatment decisions, but it cannot replace an individual consultation. Decisions depend on cancer characteristics, health status, functional reserve and personal priorities, and are best made through discussion with the treating team.
Conclusion
Age changes the context of cancer care, but it should never reduce its quality.
For many patients, surveillance becomes an increasingly appropriate strategy as priorities shift and life circumstances evolve. For others, treatment remains the right choice well into later life.
Good cancer care is not defined by how aggressive treatment is, but by how well it aligns with risk, benefit and what matters most to the individual.
About the author
Dr Deanne Soares is a Melbourne-based urologist with a subspecialist focus in robotic prostate, kidney and bladder cancer surgery.
